The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Changes in expression levels of excision repair cross-complementing group 1 (ERCC1) and dihydropyrimidine dehydrogenase (DPD) after first-line oxaliplatin-based chemotherapy for metastatic colorectal cancer: Results of a multicenter study.
Hideo Baba
No relevant relationships to disclose
Yoshifumi Baba
No relevant relationships to disclose
Shinji Uemoto
No relevant relationships to disclose
Eiji Oki
No relevant relationships to disclose
Yasuharu Ikeda
No relevant relationships to disclose
Masakazu Yamamoto
No relevant relationships to disclose
Hiroyuki Matsuda
No relevant relationships to disclose
Mitsuo Shimada
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult
Norihiro Kokudo
No relevant relationships to disclose